-
Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN) : is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?Rades, Dirk ...To compare chemoradiation with 100mg/m(2) cisplatin every three weeks to 20mg/m(2) on five days every four weeks for locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN). MATERIALS ... AND METHODS: In 230 patients receiving chemoradiation for LASCCHN, 100mg/m(2) cisplatin every three weeks (N=126) and 20mg/m(2) cisplatin on five days every four weeks (N=104) were retrospectively compared. Chemoradiation plus eleven characteristics (T-/N-classification, performance score, gender, age, tumor site, grading, surgery, radiation technique, pre-chemoradiation hemoglobin, cumulative cisplatin dose) were analyzed for locoregional control (LRC), metastases-free survival (MFS) and overall survival (OS). Chemoradiation groups were compared for adverse events. RESULTS: On univariate analyses, chemoradiation had no impact on LRC (p=0.53), MFS (p=0.67) and OS (p=0.14). On multivariate analysis of LRC, T-classification (p=0.045) and hemoglobin (p<0.001) were significant. On multivariate analysis of MFS, performance score (p=0.028) was significant. On multivariate analysis of OS, performance score (p=0.009) and hemoglobin levels (p=0.002) achieved significance. Chemoradiation with 100mg/m(2) cisplatin was associated with more pneumonia/sepsis (p=0.003), grade %2nausea/vomiting (p<0.001), grade %2 nephrotoxicity (p=0.005), grade %2 xerostomia (p=0.002), grade %3 hematotoxicity (p=0.052) and grade %2 ototoxicity (p=0.048). CONCLUDING STATEMENT: 20mg/m(2) cisplatin on five days every four weeks was associated with fewer adverse events than 100mg/m(2) cisplatin every three weeks. 100mg/m(2) cisplatin was not significantly superior to 20mg/m(2) cisplatin regarding LRC, MFS and OS. Given the limitations of a retrospective study, 20mg/m(2) cisplatin appeared preferable. The results should be confirmed in a randomized trial.Vir: Oral Oncology. - ISSN 1368-8375 (Vol. 59, Aug. 2016, str. 67-72)Vrsta gradiva - članek, sestavni delLeto - 2016Jezik - angleškiCOBISS.SI-ID - 2404475
Avtor
Rades, Dirk |
Seidl, Daniel |
Janssen, Stefan, zdravnik |
Bajrovic, Amira |
Hakim, Samer G. |
Wollenberg, Barbara |
Karner, Katarina Barbara |
Strojan, Primož |
Schild, Steven E.
Teme
rak glave in vratu |
kemoradioterapija |
cisplatin |
zdravljenje |
posledice |
chemoradiation |
LASCCHN |
higher-dose cisplatin |
treatment outcomes |
lower-dose fractionated cisplatin
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Rades, Dirk | ![]() |
Seidl, Daniel | ![]() |
Janssen, Stefan, zdravnik | ![]() |
Bajrovic, Amira | ![]() |
Hakim, Samer G. | ![]() |
Wollenberg, Barbara | ![]() |
Karner, Katarina Barbara | 18300 |
Strojan, Primož | 14576 |
Schild, Steven E. | ![]() |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.